Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Mechanisms of Resistance to Anti-CD38 Daratumumab in Multiple Myeloma

Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials, some patients do not achieve a partial response, and ultimately all patients under...

Full description

Bibliographic Details
Main Authors: Ilaria Saltarella, Vanessa Desantis, Assunta Melaccio, Antonio Giovanni Solimando, Aurelia Lamanuzzi, Roberto Ria, Clelia Tiziana Storlazzi, Maria Addolorata Mariggiò, Angelo Vacca, Maria Antonia Frassanito
Format: Article
Language:English
Published: MDPI AG 2020-01-01
Series:Cells
Subjects:
multiple myeloma
cd38 antigen
daratumumab
drug resistance
Online Access:https://www.mdpi.com/2073-4409/9/1/167

Internet

https://www.mdpi.com/2073-4409/9/1/167

Similar Items